Evidence map›Paper›PMID 31720816›Full record

Trial reportEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2020

Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in the first-line setting for Chinese patients with metastatic nasopharyngeal carcinoma.

Chaohui Jin, Hanrui Zheng, Mei Zhan, Feng Wen, Ting Xu

Abstract readClinical Trial, Phase IIIComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Trial report in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Chaohui JinDepartment of Clinical Pharmacy, West China Hospital, Sichuan University, Chengdu, China.
Hanrui ZhengDepartment of Clinical Pharmacy, West China Hospital, Sichuan University, Chengdu, China.
Mei ZhanDepartment of Clinical Pharmacy, West China Hospital, Sichuan University, Chengdu, China.
Feng WenDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Ting XuDepartment of Clinical Pharmacy, West China Hospital, Sichuan University, Chengdu, China. tingx2009@163.com.ORCID http://orcid.org/0000-0001-8727-9259
Sichuan University · CN

Funding

National Natural Science Foundation of China 81572988Science & Technology Department of Sichuan Province Funding Project 2016FZ0108 and 2018SZ0117
6 · The paper itself

Abstract

purposeA randomized phase III trial demonstrated that gemcitabine plus cisplatin (GP) prolonged progression-free survival and overall survival compared with fluorouracil plus cisplatin (FP) as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma (NPC). The cost-effectiveness analysis was designed to identify the economic option for metastatic NPC from a Chinese societal perspective.

methodsWe established a Markov model that involved three health states representing the stages of disease to simulate therapy. Survival data of clinical outcomes were derived from the trial and adjusted to quality-adjusted life years (QALYs). Transition probabilities and health utilities were obtained from the clinical trial and published literatures. The cost-effective strategy was estimated for these treatments using a willing-to-pay (WTP) threshold. A one-way sensitivity analysis was conducted to study the influences of parameters.

resultsGP treatment group produced a gain of 0.37 QALYs with an incremental cost of $2520.80, yielding an incremental cost-effectiveness ratio (ICER) of $6812.97 per QALY, compared with FP treatment ($15,530.96 versus $13,010.16). The ICER was lower than the accepted WTP threshold, which was 3 times gross domestic product per capita of China ($25,749 per QALY).

conclusionGP regimen is more cost-effective compared with FP regimen as the first-line treatment for Chinese patients with metastatic NPC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCisplatinCost-Benefit AnalysisDeoxycytidineFemaleFluorouracilGemcitabineHumansMarkov ChainsNasopharyngeal CarcinomaNasopharyngeal NeoplasmsQuality-Adjusted Life YearsCisplatinDeoxycytidineFluorouracilGemcitabineCisplatinCost-effectivenessFluorouracilGemcitabineMetastatic nasopharyngeal carcinoma

Identifiers

PMID31720816
OpenAlexW2988735335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.